Oxidative stress-modulated signaling pathways have been implicated in
carcinogenesis and
therapy resistance. The
lens epithelium derived growth factor p75 (
LEDGF/p75) is a transcription co-activator that promotes resistance to stress-induced cell death. This
protein has been implicated in inflammatory and autoimmune conditions, HIV-
AIDS, and
cancer. Although
LEDGF/p75 is emerging as a stress survival
oncoprotein, there is scarce information on its expression in human
tumors. The present study was performed to evaluate its expression in a comprehensive panel of human
cancers. Transcript expression was examined in the Oncomine cancer gene microarray database and in a TissueScan
Cancer Survey Panel quantitative polymerase chain reaction (Q-PCR) array.
Protein expression was assessed by immunohistochemistry (IHC) in
cancer tissue microarrays (TMAs) containing 1735 tissues representing single or replicate cores from 1220 individual cases (985
tumor and 235 normal tissues). A total of 21 major
cancer types were analyzed. Analysis of
LEDGF/p75 transcript expression in Oncomine datasets revealed significant upregulation (
tumor vs. normal) in 15 out of 17
tumor types. The TissueScan
Cancer Q-PCR array revealed significantly elevated
LEDGF/p75 transcript expression in prostate, colon, thyroid, and breast
cancers. IHC analysis of TMAs revealed significant increased levels of
LEDGF/p75
protein in prostate, colon, thyroid, liver and uterine
tumors, relative to corresponding normal tissues. Elevated transcript or
protein expression of
LEDGF/p75 was observed in several
tumor types. These results further establish
LEDGF/p75 as a
cancer-related
protein, and provide a rationale for ongoing studies aimed at understanding the clinical significance of its expression in specific human
cancers.